|
⚲
|
| Keyboard |
| Fairmount Funds Management LLC | |
|---|---|
| Firm | |
| Address | 200 Barr Harbor Drive Suite 400 West Conshohocken, PA 19428 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Fairmount Healthcare Co-Invest VI LP | 021-578593 | Executive Officer | |||
| Fairmount Healthcare Feeder Fund II LP | 021-334107 | Executive Officer | 944.9 M | ||
| Fairmount Healthcare Fund II LP | 021-334111 | Executive Officer | 598.3 M | ||
| Fairmount Funds Management LLC | |||||
| Fairmount Healthcare Co-Invest V LP | 021-563202 | Executive Officer | 80.3 M | ||
| Fairmount Healthcare Co-Invest IV LP | 021-528380 | Executive Officer | 41.6 M | ||
| Fairmount Healthcare Co-Invest III LP | 021-509054 | Executive Officer | 78.6 M | ||
| Fairmount Healthcare Co-Invest II LP | 021-490287 | Executive Officer | 15.2 M of 15.2 M |
24.9 M | |
| Fairmount Healthcare Co-Invest LP | 021-485732 | Executive Officer | 25.0 M of 25.0 M |
38.7 M | |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Cogent Biosciences Inc COGT
Common Stock
|
2026-03-31 | Conversion | 7,000,000 | ||
|
Cogent Biosciences Inc COGT
Common Stock
|
2026-03-31 | Sell | 7,000,000 | $34.66 | 242,620,000 |
|
Cogent Biosciences Inc COGT
Series A Convertible Preferred Stock · derivative
|
2026-03-31 | Conversion | 28,000 | $0.00 | |
|
Damora Therapeutics Inc DMRA
Stock Option (right to buy) · derivative
|
2026-03-23 | Grant | 37,313 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Common Stock
|
2026-02-09 | Option exercise | 5,809,000 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Series C Preferred Stock · derivative
|
2026-02-09 | Option exercise | 5,809 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Series C Preferred Stock · derivative
|
2026-02-09 | Option exercise | 2,904 | $0.00 | |
|
Damora Therapeutics Inc GLTO
Common Stock
|
2026-02-09 | Option exercise | 2,904,000 | $0.00 | |
|
Apogee Therapeutics Inc APGE
Common Stock
|
2026-01-22 | Sell | 1,750,000 | $76.30 | 133,525,000 |
|
Cogent Biosciences Inc COGT
Common Stock
|
2026-01-22 | Sell | 3,500,000 | $36.40 | 127,400,000 |
|
Crescent Biopharma Inc CBIO
Ordinary Shares
|
2025-12-04 | Buy | 1,360,000 | $13.41 | 18,237,600 |
|
Crescent Biopharma Inc CBIO
Pre-Funded Warrant (Right to Buy) · derivative
|
2025-12-04 | Buy | 131,434 | $13.41 | 1,762,530 |
|
Miragen Therapeutics Inc VRDN
Common Stock
|
2025-10-23 | Buy | 454,545 | $22.00 | 9,999,990 |
|
Zenas BioPharma Inc ZBIO
Common Stock
|
2025-10-07 | Buy | 316,219 | $19.00 | 6,008,161 |
|
Jade Biosciences Inc JBIO
Pre-Funded Warrant (Right to Buy) · derivative
|
2025-10-06 | Grant | 855,047 | $9.14 | 7,815,130 |
|
Jade Biosciences Inc JBIO
Common Stock
|
2025-10-06 | Grant | 1,333,126 | $9.14 | 12,184,772 |
|
Cogent Biosciences Inc COGT
Common Stock
|
2025-07-10 | Buy | 2,777,777 | $9.00 | 24,999,993 |
|
Crescent Biopharma Inc CBIO
Stock Option (Right to Buy) · derivative
|
2025-06-23 | Grant | 9,023 | $0.00 | |
|
Apogee Therapeutics Inc APGE
Stock Option (Right to Buy) · derivative
|
2025-06-17 | Grant | 14,461 | $0.00 | |
|
Apogee Therapeutics Inc APGE
Stock Option (Right to Buy) · derivative
|
2025-06-17 | Grant | 14,461 | $0.00 | |
| showing 20 of 110 most recent transactions | |||||